I agree with all of the points you mentioned in the previous post RVXoldtimer however there is one point you left out. ZCC is also entitled to royalties on any products generated by ZEL. If the 1st product to the market is ZEN-3694 and half of the royalty was sold to make a deal to keep RVX alive then the ZCC shareholders may be in a position to be unhappy. 

Selling part of the royalty is one investment decision the board of ZCC needs to make. Providing capital to RVX either through an equity financing or a loan of some kind is another but separate investment decision that board will need to make. I'm inclined to favour a combination in any type of financing. ZCC could buy a boat load of RVX shares at todays prices for next to nothing and have control of the company RVX which may be good. Lending RVX the remaining amount needed to complete the 2 trials and pay off all of their debts would also secure the IP in favour of ZCC.

Payzone is correct in sharpening his/her pencil as there may end up being better value in just leaving RVX to flounder on its own and running with ZEN-3694 without selling off half of the ZEL royalty as well. 

DM was not clear about the mechanics of the process so really we are all just blowing smoke at this time anyways. God knows we have heard all kinds of dreams in the past that never got to fruition. As a shareholder of both companies who has also been accumulating ZCC shares on the OTCBB I have the same concerns that Payzone has. With apparent success in 3 to 4 different ongoing trials I don't know if we would be better off as ZCC shareholders to focus solely on ZEN-3694 now and have additional potential from the other 1500 molecules or to have that plus ABL's potential as well. There is another 2500 molecules held by RVX as well.

The world needs both of these two leading drug candidates so whatever will get these things to market the quickest is actually the direction I'm leaning in. As I've said in the past, I will follow Dart's lead.

tada